文献速递骨肿瘤

贝叶斯信念网络能否用于估计骨肉瘤患者1年生存率?

Can a Bayesian Belief Network Be Used to Estimate 1-year Survival in Patients With Bone Sarcomas?
PubMed 文献 · Clin Orthop Relat Res · 2017-04-10

本研究基于1970年至2012年单中心3499例原发性骨肉瘤患者数据,构建贝叶斯信念网络预测1年死亡风险。内部验证显示模型预测准确性良好(AUC=0.767;95%CI,0.72-0.83),决策曲线分析表明在阈值概率大于约0.5时临床决策可基于该模型。同步转移、患者年龄和肿瘤大小对预后影响最大。

要点

  • 贝叶斯信念网络预测骨肉瘤1年死亡的AUC为0.767(95%CI,0.72-0.83)。
  • 同步转移(6.4)、年龄(3)、肿瘤大小(2.1)是1年死亡的最重要预测因素。
  • 决策曲线分析显示阈值概率低于约0.5时模型不优于假设全部存活。

核心结论

  • 贝叶斯信念网络可用于预测原发性骨恶性肿瘤患者的1年死亡率,并量化了导致死亡风险增加的主要因素。
  • 同步转移、患者年龄和肿瘤大小对预后影响最大。
  • 作者认为此类模型可作为临床决策支持工具,并在经过适当外部验证后为临床医生和患者提供与骨肉瘤治疗相关的信息。

研究设计与样本

  • 回顾性分析单中心1970年至2012年收治的所有原发性骨肉瘤患者,排除继发性转移、就诊时局部复发和良性肿瘤。
  • 机构数据库共3499例患者,其中6例(0.2%)被排除。
  • 提取患者人口学(年龄、性别)、诊断时肿瘤特征(大小、转移、病理性骨折)、生存和死因数据。
  • 贝叶斯信念网络生成变量与1年生存结局的条件概率,lift分析确定变量的层级关系。
  • 内部验证使用699例测试患者(20%数据集)确定模型准确性,并进行决策曲线分析比较所有阈值概率下的净获益(上限85.5%)。

主要发现

  • 成功生成包含五个一阶关联因素的贝叶斯信念网络,并描述其与原发性骨肉瘤诊断后生存的条件关系。
  • 内部验证显示模型预测准确性良好(AUC=0.767;95%CI,0.72-0.83)。
  • 预测1年死亡的因素按相对重要性排序为:同步转移(6.4)、患者年龄(3)、肿瘤大小(2.1)、组织学分级(1.8)、就诊时病理性骨折(1)。
  • 患者性别、肿瘤部位和非计划切除为二阶关联因素,与目标结局无直接关系。
  • 决策曲线分析显示,临床医生可基于1年模型准确制定治疗决策,而非假设所有患者或无患者能存活超过1年;对于阈值概率小于约0.5的情况,模型不优于也不劣于假设所有患者均存活。

关键数值与推荐

  • 模型内部验证AUC=0.767(95%CI,0.72-0.83)。
  • 预测1年死亡的相对重要性:同步转移6.4、患者年龄3、肿瘤大小2.1、组织学分级1.8、病理性骨折1。
  • 决策曲线分析净获益上限为85.5%。
  • 阈值概率小于约0.5时,模型不优于也不劣于假设所有患者存活。

临床怎么用

  • 作者认为该贝叶斯信念网络模型可作为临床决策支持工具,在经过适当外部验证后为临床医生和患者提供与骨肉瘤治疗相关的信息。
  • 作者认为短期预测可用于评估服务,1年死亡率已是质量指标。
  • 作者认为死亡预测因素可纳入临床试验,例如识别最不可能经历实验性毒性化疗药物副作用的患者。

局限性

  • 作者指出模型需经过适当外部验证后才能为临床医生和患者提供信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extremity sarcoma has a preponderance to present late with advanced stage at diagnosis. It is important to know why these patients die early from sarcoma and to predict those at high risk. Currently we have mid- to long-term outcome data on which to counsel patients and support treatment decisions, but in contrast to other cancer groups, very little on short-term mortality. Bayesian belief network modeling has been used to develop decision-support tools in various oncologic diagnoses, but to our knowledge, this approach has not been applied to patients with extremity sarcoma. QUESTIONS/PURPOSES: We sought to (1) determine whether a Bayesian belief network could be used to estimate the likelihood of 1-year mortality using receiver operator characteristic analysis; (2) describe the hierarchal relationships between prognostic and outcome variables; and (3) determine whether the model was suitable for clinical use using decision curve analysis. METHODS: We considered all patients treated for primary bone sarcoma between 1970 and 2012, and excluded secondary metastasis, presentation with local recurrence, and benign tumors. The institution's database yielded 3499 patients, of which six (0.2%) were excluded. Data extracted for analysis focused on patient demographics (age, sex), tumor characteristics at diagnosis (size, metastasis, pathologic fracture), survival, and cause of death. A Bayesian belief network generated conditional probabilities of variables and survival outcome at 1 year. A lift analysis determined the hierarchal relationship of variables. Internal validation of 699 test patients (20% dataset) determined model accuracy. Decision curve analysis was performed comparing net benefit (capped at 85.5%) for all threshold probabilities (survival output from model). RESULTS: We successfully generated a Bayesian belief network with five first-degree associates and describe their conditional relationship with survival after the diagnosis of primary bone sarcoma. On internal validation, the resultant model showed good predictive accuracy (area under the curve [AUC] = 0.767; 95% CI, 0.72-0.83). The factors that predict the outcome of interest, 1-year mortality, in order of relative importance are synchronous metastasis (6.4), patient's age (3), tumor size (2.1), histologic grade (1.8), and presentation with a pathologic fracture (1). Patient's sex, tumor location, and inadvertent excision were second-degree associates and not directly related to the outcome of interest. Decision curve analysis shows that clinicians can accurately base treatment decisions on the 1-year model rather than assuming all patients, or no patients, will survive greater than 1 year. For threshold probabilities less than approximately 0.5, the model is no better or no worse than assuming all patients will survive. CONCLUSIONS: We showed that a Bayesian belief network can be used to predict 1-year mortality in patients presenting with a primary malignancy of bone and quantified the primary factors responsible for an increased risk of death. Synchronous metastasis, patient's age, and the size of the tumor had the largest prognostic effect. We believe models such as these can be useful as clinical decision-support tools and, when properly externally validated, provide clinicians and patients with information germane to the treatment of bone sarcomas. CLINICAL RELEVANCE: Bone sarcomas are difficult to treat requiring multidisciplinary input to strategize management. An evidence-based survival prediction can be a powerful adjunctive to clinicians in this scenario. We believe the short-term predictions can be used to evaluate services, with 1-year mortality already being a quality indicator. Mortality predictors also can be incorporated in clinical trials, for example, to identify patients who are least likely to experience the side effects of experimental toxic chemotherapeutic agents.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Nandra R, Parry M, Forsberg J, et al. Can a Bayesian Belief Network Be Used to Estimate 1-year Survival in Patients With Bone Sarcomas? Clin Orthop Relat Res. 2017. PMID: 28397168. doi:10.1007/s11999-017-5346-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。